{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:14:38Z","timestamp":1737522878073,"version":"3.33.0"},"reference-count":18,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2024,6,7]]},"abstract":"<jats:p>The authors present a case of a thirty-eight-year-old patient with Alport syndrome. The patient had several ocular symptoms of the disease and has been treated for systemic problems in connection with Alport syndrome since he was fifteen years old. At that age the patient also underwent a kidney transplant in order to deal with renal insufficiency. To date, he still uses immunosuppressants and antihypertensives. Furthermore, the patient suffers from perceptive deafness. The patient visited our clinic in 2021 with a request to solve his high refractive error, in which the diopters were so high that it was not possible to place them in spectacles. The patient\u2019s best corrected visual acuity was 0.6 with -8.0sph\/-4.0cyl\/ax15 in the right eye and 0.7partim with -8.0sph\/-4.0cyl\/ax155 in the left eye. The autorefractometer values were -6.25sph\/-6.75cyl\/ax17 in the right eye and -6.75sph\/-6.5cyl\/ax155 in the left eye. During the eye examination we found a number of ocular manifestations that are typical of Alport syndrome. On the cornea there were opacities as a residue of corneal erosions, and at one of the following check-ups we also found a newly developed corneal erosion. Subsequently, we found an anterior lenticonus and incipient cataract. Upon performing OCT, a typical temporal macular atrophy was evident. Fundus examination in artificial mydriasis showed just a minimal manifestation of fleck retinopathy. Due to the clinical manifestation we decided to perform cataract surgery and implant a monofocal toric intraocular lens in both eyes. There were no complications during the operations, however the surgeon registered a non-standard structure of the lens capsule. The capsule was more fragile, and performing capsulorhexis was much more complicated. A week after the surgery, higher cylinder diopters were still present. A decrease of the higher diopters was noticeable one month after surgery. The time interval between the first operation and the second operation was one month. The patient was highly satisfied with result, and uncorrected visual acuity improved by over four lines. After surgery the patient needed low diopters for near as well as far distance. In the case of this patient, the ocular manifestations were detected and treated in adulthood. Nevertheless, early detection of ocular symptoms of Alport syndrome in young patients before renal failure could lead to timely start of the treatment and delay a possible renal transplant. In case of any suspicion of Alport syndrome it is advised to send the patient to a pediatrician, and at an older age to an internal medicine specialist, for further examination.<\/jats:p>","DOI":"10.31348\/2024\/28","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:01:58Z","timestamp":1737460918000},"page":"332-337","source":"Crossref","is-referenced-by-count":0,"title":["Refractive Surgery in a Patient with Alport Syndrome. A Case Report"],"prefix":"10.31348","volume":"80","author":[{"given":"Darina","family":"Posp\u00ed\u0161ilov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iveta","family":"N\u011bmcov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Pa\u0161ta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Hlad\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Vypla\u0161ilov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Havl\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"\u0160\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9vention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051\/medsci\/2020163","DOI":"10.1051\/medsci\/2020163"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"de las Rivas Ram\u00edrez N, Luque Aranda G, Rius D\u00edaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977.","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current tre-atment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345\/cep.2021.00773","DOI":"10.3345\/cep.2021.00773"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016\/j.ophtha.2021.05.031","DOI":"10.1016\/j.ophtha.2021.10.021"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmo-logists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Gui-delines. Early Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016\/j.earlhumdev.2023.105715","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"ref5","unstructured":"Kanski\u2019s Clinical Ophtalmology 2020; p.538."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520.","DOI":"10.1093\/med\/9780190050726.003.0027"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zobanov\u00e1 A, Brychc\u00ednov\u00e1 P, Autrata R, \u0160enkov\u00e1 K. Screening, Treatment and Long-term Observa-tion of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264.","DOI":"10.31348\/2018\/6\/7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103\/sjopt.sjopt_18_22","DOI":"10.4103\/sjopt.sjopt_18_22"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prematurity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038\/s41372-021-01015-8","DOI":"10.1038\/s41372-021-01015-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants. BMC Ophthal-mol. 2022 Sep 13;22(1):367. doi: 10.1186\/s12886-022-02591-9","DOI":"10.1186\/s12886-022-02591-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Tre-atment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Coun-tries. Pediatric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147\/PHMT.S391591","DOI":"10.2147\/phmt.s391591"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097\/APO.0000000000000302","DOI":"10.1097\/apo.0000000000000302"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Recent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542\/peds.2021-053924. PMID: 35948728","DOI":"10.1542\/peds.2021-053924"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301\/ejo.5000166","DOI":"10.5301\/ejo.5000166"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american asso-ciation of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542\/peds.2018-3061. Erratum in: Pe-diatrics. 2019 Mar;143(3)","DOI":"10.1542\/peds.2018-3810"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016\/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213","DOI":"10.1016\/j.ajo.2020.12.018"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389\/fphar.2022.897869","DOI":"10.3389\/fphar.2022.897869"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:02:07Z","timestamp":1737460927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2024,10,14]]}},"URL":"https:\/\/doi.org\/10.31348\/2024\/28","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"value":"1805-4447","type":"electronic"},{"value":"1211-9059","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}